Abstract Library

#4338 Spot urine 5-HIAA creatinine ratio is comparable to 24hr urine collection for diagnosis of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) constitutes up to 20% of functional neuroendocrine neoplasms and can lead to carcinoid crisis (CC), a potentially fatal complication during invasive procedures. Urine 5-hydroxyindoleacetic acid (5HIAA) is the preferred diagnostic biomarker for CS and prognostic marker for CC. 5HIAA is collected over 24-hours with strict dietary restriction for the 2 days prior as well as the day of the collection. False positive and negative results can occur due to under and over-collection. Patient inconvenience also contributes to the low request rate of this test.

Conference:

Presenting Author: Kong G

Authors: Chiang C, Gamage I, Del Olmo-Garcia M, Pasanen L, Wong H,

Keywords: carcinoid syndrome, carcinoid crisis, urine 5-HIAA, biomarker,

#4303 Carcinoid crisis: Insights from an ENETS Center of Excellence

Introduction: Neuroendocrine neoplasms (NENs) are rare tumours, with up to 30% being functional and associated with carcinoid syndrome (CS). CS commonly presents with flushing, diarrhoea, and hemodynamic instability, and can progress to carcinoid crisis (CC), a severe, potentially fatal complication during surgery or other invasive procedures. The use of prophylactic octreotide infusion peri-operatively remains controversial. The lack of a universal CC definition also poses a challenge for standardised outcome assessments.

Conference:

Presenting Author: Del Olmo-Garcia M

Authors: Del Olmo-Garcia M, Kong G, Wong H, Michael M, Ismail H,

Keywords: carcinoid syndrome, carcinoid crisis, somatostatin analogue, peri-operative management,

#2010 A case of Carcinoid Crisis Despite High Dose Somatostatin Analogue Therapy Peri-operatively

Introduction: Carcinoid crisis is a life threatening endocrine emergency. Somatostatin analogues (SSA) are recommended as prophylactic administration before invasive procedures. It remains unclear whether there is an optimal dose of prophylactic somatostatin analogue therapy in the peri-operative period.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pitfield D, Casey R, Seetho I, Shaw A, Buscombe J,

Keywords: carcinoid syndrome, carcinoid crisis, octreotide, surgery,

#1607 Perioperative Carcinoid Crisis During Surgery- Who Benefits from Octreotide?

Introduction: Carcinoid crisis, as an entity is poorly defined, but can be seen in patients with small bowel NET after open bowel surgery or tumour unrelated procedures as cardiovascular instability (CI)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Elgendy K, Johnson S, French J, White S, Charnley R,

Keywords: Octreotide, carcinoid crisis,

#1296 The Application of Octreotide in a SINET Patient with Carcinoid Syndrome, Carcinoid Heart Disease and Carcinoid Crisis: A Case Report

Introduction: In Chinese population, small intestinal neuroendocrine tumor (SINET) only accounts for 2.2% of gastroenteropancreatic NET, while carcinoid syndrome, carcinoid heart disease (CHD) and carcinoid crisis are rarer.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Chen J

Authors: Chen L, Zhang Y, Chen M, Chen J,

Keywords: Octreotide, small intestinal neuroendocrine tumor, carcinoid syndrome, carcinoid heart disease, carcinoid crisis,